Amgen Obtains Broader Label For Denosumab With Oncology Indication
Executive Summary
FDA approved Amgen’s bone-strengthening drug denosumab Nov. 18 for its first oncology indication, prevention of skeletal-related events – bone fractures or bone pain requiring radiation treatment – in patients with bone metastases from solid tumors.
You may also be interested in...
On Amgen’s Agenda: Bring Biologics To Primary Care
The big biotech is investing heavily in two late-stage drugs – one for high cholesterol and the other for osteoporosis – that will test its ability to expand its specialty marketing savvy into primary care markets. Denosumab, launched in 2010 for osteoporosis under the brand name Prolia, was a first step, but investors see bigger opportunities ahead.
Amgen Needs To Show Xgeva Does More Than Delay Bone Metastases, ODAC Says
Measurement of a downstream endpoint, such as delay in skeletal-related events, could have been better than radiographic scans to assess efficacy of denosumab in delaying bone metastases in high-risk castration-resistant prostate cancer patients, several ODAC members contend.
New Oncology Indications Should Continue Denosumab’s Upward Trajectory
Already on an upward trajectory in oncology uses, Amgen’s denosumab, known as Prolia and Xgeva, got a bit of a boost with FDA approval of two new indications for treatment-induced bone loss in prostate and breast cancer – though neither is expected to add much to the bottom line.